However, the complicated logistics of granulocyte collection, the need for pre-treating donors with granulocyte colony-stimulating factor (G-CSF) or steroids, difficulties in collecting a sufficient number of good quality granulocytes and the limited storage time (24 h); all hamper the utility of granulocyte transfusion for correcting neutropenia, and may contribute to the inconclusive results observed in clinical trials. The gene discussed is CSF3; the disease is neutropenia.